Purchase this article with an account.
R. B. Dichtchekenian, L. T. Dalfre, G. Z. Ramos, V. C. C. Afonso, A. F. Bordon; Minimally Classic or Occult With No Classic Choroidal Neovascularization Secondary to Age-Related Macular Degeneration Treated by an Alternative Regimen of Intravitreal Bevacizumab: Bemino Study. Invest. Ophthalmol. Vis. Sci. 2008;49(13):330. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The primary objectives are to evaluate the visual acuity (VA) and ocular coherence tomography (OCT) macular thickness changes with the use of intravitreous bevacizumab (IVB) in the treatment of minimally classic (MC) or occult with no classic (ONC) subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The secondary objective is to evaluate safety of this procedure.
This is an open-label, prospective, non-randomized, non-controlled, interventional, consecutive case series. Patients with MC or ONC due to AMD were enrolled. Patients were treated with 2.0mg IVB at baseline, 3 months, 6 months, 9 months, and 12 months. VA was measured using the ETDRS chart. OCT was performed at baseline and at each follow-up visit. Patients with follow-up shorter than 3 months were excluded from this analysis. Fluorescein angiograms were performed at baseline, 45 days, 90 days, and every 3 months thereafter.
We included 7 eyes of 7 patients. Five were male. Three were right eyes. Mean age was 72.4 years-old (56-84 yr-old). Mean follow-up was 201.2 days (90-360 days). Five patients were MC and 2 patients were ONC. Mean best-corrected visual acuity was 1.24, 1.15, 1.06, 1.03 and 1.15 logMAR units at baseline, 3 months, 6 months, 9 months and 12 months, respectively. No patient experienced loss of VA during follow-up. Mean OCT macular thickness was 307.2µm, 296.7µm, 266µm, 240.3µm and 229µm at baseline, 3 months, 6 months, 9 months and 12 months, respectively. No ocular or systemic adverse effect occurred during the follow-up period.
In a mean follow-up of 201.2 days, 2.0mg of bevacizumab injected every 3 months stabilized or improved VA in patients with MC or ONC due to AMD and was safe throughout the study.
This PDF is available to Subscribers Only